Data are presented as medians with the range in parenthesisRBT = rifabutin; OD = once daily; TPW = three times per week; Cmax = peak concentration; C0 = trough concentration. All patients: data pooled
This study was designed to evaluate if subjects who took 600 mg of abacavir and 300 mg of lamivudine once-daily as a single tablet were just as likely to have adverse events compared to subjects who
The probability of administering immunotherapy (PI(Dayi)) in each day of the treatment cycle and the conditional probability PI(n|Dayi) of administering n doses of immunotherapy for n = 1, 2, 3, 4.